Skip to main content
Premium Trial:

Request an Annual Quote

Ivan Richards Joins Sirna; Catherine Connolly, Kathy Lambert Go to CAT; Geoffrey Duyk to Leave Exelixis; and Others

NEW YORK, Nov. 5 (GenomeWeb News) -  Ivan Richards has been appointed senior director of pharmacology at Sirna Therapeutics, the company said Nov. 4.


Richards comes to Sirna from Pfizer, and prior to the merger, Pharmacia, where he was a scientist, senior fellow, and discovery team leader.


Ian Gray has been appointed head of research at Paradigm Therapeutics Singapore, a new Singapore R&D subsidiary of the Cambridge, UK-based company.


Gray comes to Paradigm Therapeutics from GlaxoSmithKline, where he was manager, molecular genetics in the company's UK genetics research division.


Catherine Connolly has joined Cambridge Antibody Technology as vice president of human resources, and Kathy Lambert has joined the company as vice president of quality, a position in which she will be responsible for ensuring compliance with good manufacturing practice, good clinical practice, and good laboratory practice, the company said Nov. 3.


Connolly comes to CAT, of Cambridge, UK, from Simpay, a mobile phone payments company where she was interim human resources advisor. Before joining Simpay, Connolly held human resources positions at Mediaedge, KPMG, and National Westminister Bank.


Lambert joints CAT from Xenova Research, where she was director, quality and regulatory affairs. Before that, she was director of UK operations/FDA responsible head at Celltech Biologics, which is now Lonza.


Edward McCabe has  joined the board of advisors at GeneFluidics, of Monterey Park, Calif., the company said Nov. 3.


McCabe is chair of the department of pediatrics at UCLA Medical School. He is also chair of the US Department of Health and Human Services Secretary's Advisory Committee on Genetics, Health, and Society.


Genefluidics said it is developing nanotechnology that electrochemically senses target analytes, and performs automated sample preparation.


Geoffrey Duyk will leave his post of president, research and development, and chief scientific officer at Exelixis at the end of the year to pursue "other professional opportunities," the company said Oct. 30.


"I am looking forward to opportunities to help build promising entrepreneurial companies or to participate in emerging opportunities in the public sector," Duyk said in a statement.


Frank McCormick, who serves on Exelixis' board of directors, and is director of the University of California, San Francisco Comprehensive Cancer Center, will step up his advisory role on the company's R&D.


Greg Plowman, the company's senior vice president of research, Michael Morrissey, the company's senior vice president of discovery research, and Jeffrey Latts, the company's chief medical officer, will remain in their current roles, the company said.


Duyk joined Exelixis in April 1997 from Millennium Pharmaceuticals, where he was vice president of genomics and a member of the original staff. Before his work at Millennium, he was an assistant professor at Harvard Medical School in the department of genetics.



The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.